Inhibition of the enzyme raises blood levels of both and leads to feelings of happiness. Gleevec (imatinib), a drug that dramatically increases the survival rate in chronic myelocytic leukemia (CLM), was developed based on the finding that CML patients produce an abnormal version of the enzyme tyrosine kinase, which in turn leads to an overproduction of white blood cells.